Hims Stock Crashes
Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic ...
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others ...
Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...
Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback